{"entity":{"id":"nct06190951","kind":"trial","name":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","aka":[],"tldr":"A phase 2 trial of Cemiplimab, Fianlimab in melanoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.","summary":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma is a phase 2 interventional study registered as NCT06190951 by Regeneron Pharmaceuticals, with 151 participants enrolled, started 2024-09-18 and due to reach its primary completion in 2026-11-02. Interventions recorded: cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06190951","url":"https://clinicaltrials.gov/study/NCT06190951"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cemiplimab","fianlimab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06190951","phase":"2","setting":"A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma","sponsor":"Regeneron Pharmaceuticals","participation":[{"nct":"NCT06190951","source":"https://clinicaltrials.gov/study/NCT06190951","fetchedAt":"2026-10-07T16:54:18.114Z","studySha256":"23724054ba8c401b2d69387ea0d93ba2b8de3c980bb383b4a5b1c04d0c412a62","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-02-10","leadSponsor":"Regeneron Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":151,"enrolmentType":"ACTUAL","siteCount":104,"recruitingSiteCount":0,"countries":["Australia","Austria","Canada","France","Germany","Italy","Spain","United States"]}],"started":"2024-09-18","startedType":"actual","enrolled":151,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06190951/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"},{"id":"fianlimab","kind":"drug","name":"Fianlimab","route":"/drugs/fianlimab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}